A drug pipeline is the portfolio of therapeutic candidates a company or organisation is developing, usually described by stage (discovery, preclinical, phase I–III, registration). It reflects both current assets and future potential revenue. For clinical and digital‑health audiences, understanding this term is useful when evaluating AI vendors’ claims about “expanding the pipeline” or “amplifying discovery across multiple therapeutic areas.”